A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943

NCT06313528 · Completed

Last updated 2026-05-28

This clinical trial is testing how a medication called LY3437943 affects the amount of calories consumed by adults with obesity during lunch and dinner.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 85 people

Who can join Ages 18–60 · all sexes

Timeline Started 2024-03 · est. completion 2025-08

Where 3 sites · United States

What this study is testing ClinicalTrials.gov NCT06313528 ↗

Description as written by the study sponsor.

The main purpose of the study is to look at the effect of the study drug compared to placebo on calorie intake, energy metabolism, and appetite. The study will last up to 6 months and may include up to 20 visits.

Treatments tested

LY3437943 Drug

Administered SC
Placebo Other

Administered SC

Main thing measured	Change from Baseline in Total Calorie Intake at Lunch and Dinner (Combined)
Sponsor	Eli Lilly and Company
Conditions studied	Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06313528 ↗